Results 1 to 10 of about 1,537,551 (243)
bioRxiv, 2021 Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis for COVID-19. However, ongoing evolution of SARS-CoV-2 can render monoclonal antibodies ineffective.
Tyler N. Starr +3 more
semanticscholar +1 more source
bioRxiv, 2020 The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 800 laboratory-confirmed human infections, including 25 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine.
Xiao-long Tian +10 more
semanticscholar +1 more source
A human monoclonal antibody blocking SARS-CoV-2 infection
Nature Communications, 2020 The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking.
Chunyan Wang +9 more
semanticscholar +1 more source
Mediation Analyses for the Effect of Antibodies in Vaccination [PDF]
Journal of Causal Inference, 2024, 12:20220043, 2022 We review standard mediation assumptions as they apply to identifying antibody effects in a randomized vaccine trial and propose new study designs to allow identification of an estimand that was previously unidentifiable. For these mediation analyses, we partition the total ratio effect (one minus the vaccine effect) from a randomized vaccine trial ...
arxiv +1 more source
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
New England Journal of Medicine, 2020 Background LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19).
J. Lundgren +45 more
semanticscholar +1 more source
Asian Pacific Journal of Allergy and Immunology, 2020 Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently ...
B. Shanmugaraj +3 more
semanticscholar +1 more source
Using cluster theory to calculate the experimental structure factors of antibody solutions [PDF]
, 2022 Monoclonal antibody solutions are set to become a major therapeutic tool in the years to come, capable of targeting various diseases by clever designing their antigen binding site. However, the formulation of stable solutions suitable for patient self-administration typically presents challenges, as a result of the increase in viscosity that often ...
arxiv +1 more source
Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis
Aging and Cancer, Volume 3, Issue 3-4, Page 133-146, September-December 2022., 2022 One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen +3 more
wiley +1 more source
Antibody binding reports spatial heterogeneities in cell membrane organization [PDF]
, 2022 The spatial organization of cell membrane glycoproteins and glycolipids is critical for mediating the binding of ligands, receptors, and macromolecules on the plasma membrane. However, we currently do not have the methods to quantify the spatial heterogeneities of macromolecular crowding on live cell surfaces.
arxiv +1 more source
New England Journal of Medicine, 2001 BACKGROUND The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor.
D. Slamon +11 more
semanticscholar +1 more source